SEC Form 4 · accession 0001831215-26-000005
Immunome Inc. · IMNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kinney Horn
Officer — CHIEF BUSINESS OFFICER
Period of report
Aug 4, 2026
Accepted (ET)
Aug 6, 2026 · 6:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001472012
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 4, 2026 | M | 50,366 | $12.92 | A | 50,366 | D | |
| Common Stock | Aug 4, 2026 | M | 40,250 | $10.60 | A | 90,616 | D | |
| Common StockF2 | Aug 4, 2026 | S | 90,616 | $25.09 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $12.92 | Aug 4, 2026 | M | 50,366 | D | — | Aug 8, 2034 | Common Stock | 50,366 | 78,542 | D |
| Employee Stock Option (right to buy)F4 | $10.60 | Aug 4, 2026 | M | 40,250 | D | — | Jul 28, 2035 | Common Stock | 40,250 | 120,750 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
- F2The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F325% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
- F425% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years.